UA70909C2 - Recombinant adenovirus expression vector, pharmaceutical composition, and gene therapy aimed at inhibiting cancer cell proliferation - Google Patents
Recombinant adenovirus expression vector, pharmaceutical composition, and gene therapy aimed at inhibiting cancer cell proliferationInfo
- Publication number
- UA70909C2 UA70909C2 UA96052054A UA96052054A UA70909C2 UA 70909 C2 UA70909 C2 UA 70909C2 UA 96052054 A UA96052054 A UA 96052054A UA 96052054 A UA96052054 A UA 96052054A UA 70909 C2 UA70909 C2 UA 70909C2
- Authority
- UA
- Ukraine
- Prior art keywords
- expression vector
- gene therapy
- recombinant adenovirus
- pharmaceutical composition
- cancer cell
- Prior art date
Links
Abstract
This invention provides a recombinant adenovirus expression vector characterized by the total deletion of the E1a, E1b and adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14266993A | 1993-10-25 | 1993-10-25 | |
| UA08246007 | 1994-05-19 | ||
| PCT/US1994/012235 WO1995011984A2 (en) | 1993-10-25 | 1994-10-25 | Recombinant adenoviral vector and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA70909C2 true UA70909C2 (en) | 2004-11-15 |
Family
ID=74202586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA96052054A UA70909C2 (en) | 1993-10-25 | 1994-10-25 | Recombinant adenovirus expression vector, pharmaceutical composition, and gene therapy aimed at inhibiting cancer cell proliferation |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA70909C2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11311583B2 (en) | 2012-10-17 | 2022-04-26 | Vascular Biogenetics Ltd. | Treatment methods using adenovirus |
-
1994
- 1994-10-25 UA UA96052054A patent/UA70909C2/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11311583B2 (en) | 2012-10-17 | 2022-04-26 | Vascular Biogenetics Ltd. | Treatment methods using adenovirus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2173975A1 (en) | Recombinant adenoviral vector and methods of use | |
| AU2853395A (en) | Recombinant vectors derived from adenovirus for use in gene therapy | |
| NZ332634A (en) | Isolated autophosphorylating polypeptide having phosphoinositide-3-kinase activity | |
| Miller et al. | Expression of cloned bovine adrenal rhodanese. | |
| WO2000012740A3 (en) | Adenoviruses deleted in the iva2, 100k and/or preterminal protein sequences | |
| AU7177394A (en) | Vertebrate apoptosis gene: compositions and methods | |
| Kitani et al. | Purification and some properties of a protein inhibitor (antizyme) of ornithine decarboxylase from rat liver. | |
| HUP0301318A2 (en) | Replication-defective recombinant adenovirus with mutated major late promoter | |
| BG100771A (en) | Hematopoeic protein and ways and methods for its preparation | |
| RU96112150A (en) | RECOMBINANT Adenovirus VECTOR AND WAYS OF ITS APPLICATION | |
| SG141233A1 (en) | Control of gene expression | |
| CY1111931T1 (en) | BODIES FOR DISEASE EDUCATION | |
| IL136104A0 (en) | Vector for tissue-specific replication and gene expression | |
| HK1092481A1 (en) | Polypeptides having binding affinity for her2 | |
| EP1180932A4 (en) | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof | |
| NZ505063A (en) | Pharmaceutical use of long pentraxin PTX3 in treating tumour conditions | |
| EP1214098A4 (en) | Capsid-modified recombinant adenovirus and methods of use | |
| NZ334827A (en) | High-capacity adenoviral vectors suitable for adenoviral-based gene therapy | |
| BR9811865A (en) | Isolation of a new senescence factor gene, p23 | |
| AU4024097A (en) | Homocysteine desulphurase from the protozoan trichomonas vaginalis | |
| EP1702071A4 (en) | Transactivation system for mammalian cells | |
| WO2003008449A8 (en) | Ntb-a, a surface molecule involved in natural killer cells activity | |
| UA70909C2 (en) | Recombinant adenovirus expression vector, pharmaceutical composition, and gene therapy aimed at inhibiting cancer cell proliferation | |
| JP2002512785A5 (en) | ||
| EP1418948A4 (en) | Replicating adenovirus vectors |